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Background
Treating chronic HCV/HBV-infected patients with con-
comitant rheumatoid arthritis (RA) may be a challenge
to the clinician. The liver disease limits to some degree
the treatment for the rheumatic disease as the drugs
used are hepatotoxic or at risk of infection reactivation.
The aim of the study is to evaluate the particularities
and the safety of RA treatment in patients with both
conditions and to investigate the prevalence of HBV/
HCV-infections in RA patients.
Methods
We performed a cross-sectional analysis of all HCV/HBV
or co-infected patients with concomitant RA admitted
between 2009-2014, assessing the clinical, laboratory,
treatment data and verifying the statistic correlations.
Results
The study included 66 patients, with both chronic liver
infection and RA, of which 35 (53%) patients had HCV,
24 (36.3%) had HBV and 7 (10.6%) were co-infected. The
median age was 61 ± 11 years, sex ratio male/female 13/
53. The HCV-infected patients had a very active rheu-
matic disease activity score (DAS28) (5.03 ± 1.43) while
the HBV and co-infected patients had a moderate DAS
(DAS28 = 4.06 ± 1.68), respectively DAS28 (3.05 ± 1.74)
(p = 0.015). Therapeutic options include disease-modify-
ing anti-rheumatic drugs (DMARDs), classic or biologic
as well as corticosteroids (CS). In our study, most
patients, 25 (37.8%) received hydroxychloroquine, 9
(13.6%) patients received methotrexate and 7 (10.6%)
patients sulphasalazine alone. Combinations included
hydroxychloroquine + sulphasalazine in 5 (7.57%)
patients and methotrexate + hydroxychloroquine in 4
(6%) patients.
In 1 (14.2%) patient out of 7 receiving biologic treatment
6 (85%) infliximab, 1 (14, 2%) etanercept, 5 (71, 42%)
rituximab – current or prior treatment, reactivation of the
HBV infection occurred, during the 6th cycle of therapy.
The rise in the liver enzymes, leading to discontinuation
were seen in 14 (56%) patients receiving methotrexate, fol-
lowed by 7 (10.6%) patients receiving sulfasalazine, and 1
(4.3%) in the hydroxychloroquine group. Significantly
more patients in the HCV group 27 (80%), compared with
the HBV group 24 (45.8%), had an active disease and were
given low dose corticosteroids (p = 0.028).
Conclusion
The presence of the liver infection limits to some degree
the therapy for RA. Classic DMARDs such as methotrex-
ate should be closely monitored as they proved most
hepatotoxic and led to frequent discontinuation. Hydro-
xychloroquine was best tolerated. HCV-patients with RA
often require more aggressive therapy, including biolo-
gics, which also have to be used with caution. The preva-
lence of HCV infection was higher than HBV infection in
the study RA group. Also HCV-infected patients had a
more active rheumatic disease and used corticosteroids
more frequently.
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